Stay updated on SubQ Efgartigimod in CIDP Clinical Trial
Sign up to get notified when there's something new on the SubQ Efgartigimod in CIDP Clinical Trial page.

Latest updates to the SubQ Efgartigimod in CIDP Clinical Trial page
- CheckyesterdayChange DetectedThe page now indicates that enrollment is closed, and new guidance sections related to reading the study record and joining the study have been added. A formatting change to the Intervention/Treatment label and a revision note were also applied.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page shows Revision: v3.5.4, replacing the previous v3.5.3. This indicates a minor internal update to the trial entry rather than changes to the study details or results.SummaryDifference0.0%

- Check37 days agoChange DetectedTaiwan enrollment location updated: Taoyuan District, Taiwan was removed and Taoyuan, Taiwan was added to the study's locations.SummaryDifference0.0%

- Check44 days agoChange DetectedA new Revision: v3.5.3 was added, replacing the previous Revision: v3.5.2. This indicates a small metadata update to the page, not affecting study content.SummaryDifference0.0%

- Check52 days agoChange DetectedRevision updated to v3.5.2. Previous revision v3.5.0 was removed.SummaryDifference0.0%

- Check73 days agoChange DetectedCIDP is added as a listed condition, and a Genetic and Rare Diseases Information Center resource link is included.SummaryDifference0.1%

Stay in the know with updates to SubQ Efgartigimod in CIDP Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SubQ Efgartigimod in CIDP Clinical Trial page.